Siti Internazionali
Se hai scelto di non accettare i cookie di profilazione e tracciamento, puoi aderire all’abbonamento "Consentless" a un costo molto accessibile, oppure scegliere un altro abbonamento per accedere ad ANSA.it.
Ti invitiamo a leggere le Condizioni Generali di Servizio, la Cookie Policy e l'Informativa Privacy.
In evidenza
In evidenza
Temi caldi
Comunicato stampa
Comunicato stampa
Responsabilità editoriale di Business Wire
Comunicato stampa - Responsabilità editoriale di Business Wire
Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, has released its latest industry report, Gastric Cancer- Global Clinical Trial Landscape (2024) .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240903559744/en/
This report details the current gastric cancer (GC) research environment as it continues to evolve, as well as offering key insights into the trends that are expected to extend into the near future. The report examines the global state of clinical trials, drug discovery, and emerging therapeutic strategies, while also highlighting the significant progress in understanding and treating GC, showcasing promising therapeutic pipelines with potential benefits for patients and associated organizations worldwide.
The Novotech research analyst team provides these expert reports monthly, highlighting key metrics on the current status of specific diseases and outlining future trends that may impact the development of treatments. This is provided completely free of charge.
Key takeaways from the report:
With ongoing clinical trials, innovative drug development, evolving therapeutic strategies, and continued investment of capital, the future of GC treatment looks promising.
For more information and to download the full report free of charge, please visit Novotech's website or contact our media relations team.
About Novotech Novotech-CRO.com
Founded in 1997, Novotech is a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech companies to accelerate the development of advanced and novel therapeutics at every phase.
Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, the Asia-Pacific Contract Research Organization Company of the Year Award since 2006.
The Company offers a comprehensive suite of services including laboratories, Phase I facilities, drug development consulting, regulatory expertise, and has experience with over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. With a presence in 34 office locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a trusted end-to-end strategic partner of choice.
For more information or to speak to an expert team member visit www.Novotech-CRO.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20240903559744/en/
Toyna Chin
mediacontact@novotech-cro.com
USA: +1 415 364 8135
Permalink: http://www.businesswire.com/news/home/20240903559744/en
Comunicato stampa - Responsabilità editoriale di Business Wire
Ultima ora